Clinical TrialMay 18, 2026, 04:26 PM
Quince Therapeutics LAM-001 Phase 2a shows 67.4m 6MWD improvement in PH-ILD
AI Summary
Quince Therapeutics announced positive Phase 2a data for LAM-001, an inhaled rapamycin, in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study demonstrated clinically meaningful improvements across functional, hemodynamic, and biomarker measures, including a 67.4-meter improvement in 6MWD and a 33.9% reduction in PVR in PH-ILD patients. Based on these encouraging results, the company plans to initiate a Phase 2b trial in PH-ILD in mid-2026, with data expected in the first quarter of 2028, and also has ongoing and planned studies for other indications.
Key Highlights
- LAM-001 Phase 2a study showed 6MWD improvement of 67.4 meters in PH-ILD subgroup (N=4).
- PVR (supine) reduced by 33.9% in PH-ILD subgroup and 28.1% in evaluable population (N=6).
- NT-proBNP decreased by 28.8% in PH-ILD subgroup and 29.0% in evaluable population.
- VO2 Max improved by 6.7% in PH-ILD subgroup and 5.4% in evaluable population.
- All evaluable patients transitioned from Functional Class III to Functional Class II by Week 24.
- Phase 2b trial in PH-ILD to initiate mid-2026, with topline data anticipated Q1 2028.
- Phase 2 study in BOS anticipates data in Q1 2027.
- Phase 2 study in sarcoidosis-associated PH (SAPH) planned for late 2026.
Price Impact
More from QNCX